- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-2-2-2-mer
- Ligands
- 8 x Y01: CHOLESTEROL HEMISUCCINATE(Non-covalent)(Covalent)
- 2 x PC1: 1,2-DIACYL-SN-GLYCERO-3-PHOSPHOCHOLINE(Non-covalent)(Covalent)
PC1.4: 6 residues within 4Å:- Chain A: I.91, L.95, K.98, L.147, L.154, I.155
5 PLIP interactions:5 interactions with chain A- Hydrophobic interactions: A:I.91, A:I.91, A:L.95, A:L.154, A:I.155
PC1.15: 6 residues within 4Å:- Chain B: I.91, L.95, K.98, L.147, L.154, I.155
4 PLIP interactions:4 interactions with chain B- Hydrophobic interactions: B:I.91, B:L.95, B:L.154, B:I.155
- 10 x MYS: PENTADECANE(Non-covalent)(Non-functional Binders)
MYS.5: 3 residues within 4Å:- Chain A: I.88, I.91, F.102
3 PLIP interactions:3 interactions with chain A- Hydrophobic interactions: A:I.88, A:I.91, A:F.102
MYS.6: 3 residues within 4Å:- Chain A: S.85, L.103, M.105
1 PLIP interactions:1 interactions with chain A- Hydrophobic interactions: A:L.103
MYS.7: 2 residues within 4Å:- Chain A: T.39
- Ligands: MYS.8
No protein-ligand interaction detected (PLIP)MYS.8: 3 residues within 4Å:- Chain A: W.41, L.108
- Ligands: MYS.7
2 PLIP interactions:2 interactions with chain A- Hydrophobic interactions: A:W.41, A:L.108
MYS.9: 0 residues within 4Å:- (No contacts)
No protein-ligand interaction detected (PLIP)MYS.16: 2 residues within 4Å:- Chain B: I.88, F.102
3 PLIP interactions:3 interactions with chain B- Hydrophobic interactions: B:I.88, B:F.102, B:F.102
MYS.17: 2 residues within 4Å:- Chain B: S.85, M.105
No protein-ligand interaction detected (PLIP)MYS.18: 2 residues within 4Å:- Chain B: T.39
- Ligands: MYS.19
No protein-ligand interaction detected (PLIP)MYS.19: 2 residues within 4Å:- Chain B: W.41
- Ligands: MYS.18
No protein-ligand interaction detected (PLIP)MYS.20: 1 residues within 4Å:- Chain B: L.44
1 PLIP interactions:1 interactions with chain B- Hydrophobic interactions: B:L.44
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Kumar, A. et al., Binding mechanisms of therapeutic antibodies to human CD20. Science (2020)
- Release Date
- 2020-08-26
- Peptides
- B-lymphocyte antigen CD20: AB
Rituximab Fab Heavy Chain: CE
Rituximab Fab Light Chain: DF - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CE
HD
DF
L - Membrane
-
We predict this structure to be a membrane protein.
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-2-2-2-mer
- Ligands
- 8 x Y01: CHOLESTEROL HEMISUCCINATE(Non-covalent)(Covalent)
- 2 x PC1: 1,2-DIACYL-SN-GLYCERO-3-PHOSPHOCHOLINE(Non-covalent)(Covalent)
- 10 x MYS: PENTADECANE(Non-covalent)(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Kumar, A. et al., Binding mechanisms of therapeutic antibodies to human CD20. Science (2020)
- Release Date
- 2020-08-26
- Peptides
- B-lymphocyte antigen CD20: AB
Rituximab Fab Heavy Chain: CE
Rituximab Fab Light Chain: DF - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CE
HD
DF
L - Membrane
-
We predict this structure to be a membrane protein.